Background-Prior studies have suggested that blacks with acute ST-segment-elevation myocardial infarction have increased bleeding risks with fibrinolysis relative to whites, yet these data were quite limited. Additionally, it is unknown whether there are racial differences in bleeding risks among patients with ST-segment-elevation myocardial infarction receiving primary percutaneous coronary intervention. Methods and Results-We evaluated data on blacks and whites with ST-segment-elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention from the National Registry of Myocardial Infarction (NRMI)-4 and 5 participating centers between July 2000 and December 2006. We compared differences between the 2 groups in rates of in-hospital major bleeding and mortality, adjusted with logistic regression analyses. In fibrinolytic-treated patients with ST-segment-elevation myocardial infarction, the bleeding rates were higher among blacks (nϭ2283) than whites (nϭ42 243; 10.9% versus 10.3%; adjusted odds ratio, 1.21; 95% confidence interval, 1.02-1.43). Similarly, in patients receiving primary percutaneous coronary intervention, the bleeding rates were higher in blacks (nϭ2826) than in whites (nϭ46 332; 10.3% versus 7.8%; adjusted odds ratio, 1.33; 95% confidence interval, 1.13-1.56). Bleeding was associated with higher risk of death in both ethnic groups. However, there was no overall racial difference in in-hospital mortality among those with bleeding or without bleeding treated with either fibrinolysis or primary percutaneous coronary intervention. Conclusions-Blacks with ST-segment-elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention had a higher risk of bleeding events than their white counterparts. Bleeding was associated with a similar increased risk of death in both ethnic groups treated by either reperfusion strategy. (Circulation. 2012;125:1727-1734.)
(PPCI) has become the preferred reperfusion strategy for patients with acute ST-segment-elevation myocardial infarction (STEMI), fibrinolytic therapy still is used in about a third of STEMI patients in the United States and in a larger cohort globally. 1 Additionally, these agents are used in several other indications such as the treatment of acute ischemic stroke, acute pulmonary embolism, and deep vein thrombosis; they also are instilled locally for clearing in-dwelling intravenous catheters and grafts used for dialysis. [2] [3] [4] [5] Thus, understanding the safety and effectiveness of these drugs in patients of different ethnic background remains important.
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Bleeding is a dreaded adverse event in patients who receive reperfusion therapy for STEMI. 1 Case series and clinical trials have suggested that blacks with STEMI receiving fibrinolysis have a higher bleeding risk than their white counterparts 6 -9 that portends poor short-and long-term mortality. However, these studies involved limited numbers of subjects and/or highly selected patients enrolled in clinical trials.
In response to these preliminary safety concerns in blacks (and potentially in other nonwhite ethnicities), the Food and Drug Administration mandated postmarketing data collection to monitor bleeding and other events among patients of different ethnicities with STEMI treated with fibrinolysis. However, to date, the bleeding risk of fibrinolytic therapy in STEMI patients has not been evaluated in community practice.
Similarly, whether there are ethnic differences in the risk of bleeding and its related outcomes among patients undergoing PPCI is unknown. The reason is that even the largest PPCI trials have not enrolled a sufficient number of patients of African descent to allow inferences about the relationship of race with bleeding and outcomes. 10 -13 The present study is a retrospective analysis of data on patients receiving reperfusion therapy for STEMI enrolled in the National Registry of Myocardial Infarction (NRMI). 14 -18 The objectives of this analysis were to determine whether race-black versus white-has a differential impact on moderate or severe bleeding risk in patients receiving fibrinolysis or PPCI and to evaluate the relationship of race and moderate or severe bleeding with in-hospital mortality and whether this differed by type of reperfusion.
Methods

Study Population
The methods and patient populations of this registry have been published previously. 14 -18 Patients with acute MI, both STEMI and non-STEMI, were enrolled in this registry. For this analysis, we included patients with a principal discharge diagnosis code of 410X1 who had STEMI or presumed new left bundle-branch block on ECG and were treated with either fibrinolysis or PPCI within 12 hours of their first hospital arrival. Patients in hospitals that did not enroll both whites and black patients with STEMI treated with reperfusion therapy were excluded (3 hospitals). Patients were also excluded if they were of other racial descent besides white or black, presented with cardiogenic shock, had a "do not resuscitate" order active at the time of presentation, received facilitated PCI, or were transferred out of the hospital. The remaining patients with STEMI enrolled at 1138 sites were stratified on the basis of their primary reperfusion strategy (fibrinolysis or PPCI) and substratified on the basis of race into 4 groups: whites treated with fibrinolysis, whites treated with PPCI, blacks treated with fibrinolysis, and blacks treated with PPCI.
Data Collection and Definitions
Data were collected prospectively on the case report form in NRMI. Investigators were required to check a single box on the case report form indicating whether patients were white, black, Hispanic, Asian, American Indian, or other. The clinical end-point definitions were provided to all sites. Information on bleeding was collected as follows: major bleeding, defined as intracerebral bleeding or hemorrhage or bleeding resulting in hemodynamic compromise requiring treatment or death, and moderate bleeding, defined as bleeding requiring transfusion.
Statistical Analysis
We compared the differences in clinical features, angiographic characteristics, and outcomes between blacks and whites treated with fibrinolysis versus PPCI. Univariable comparisons between the groups were made with the Pearson 2 or Fisher exact test (when cells had expected counts Յ5) for categorical/binary variables. For continuous variables, a normality test was performed within each group, and if the normality condition was not satisfied, then a nonparametric P value was calculated from the Wilcoxon rank-sum test. Otherwise, the P values were based on the type III sums of squares from a general linear model procedure.
Multivariable logistic regression analysis was performed to evaluate factors independently associated with the risk of bleeding in patients with STEMI receiving any reperfusion therapy. Besides other variables previously shown to be associated with risk on bleeding, 9 race (black versus white) was entered into the model as a covariate, and the race-by-treatment (fibrinolysis versus PPCI) interaction was examined. The following baseline factors (in addition to race) were included in the model after appropriate transformation and model-selecting procedures: age, medical history (myocardial infarction, smoking, diabetes mellitus, coronary artery bypass surgery, stroke, and hypertension), findings on physical examination (Killip class, systolic blood pressure, heart rate, height, weight, infarct location, serum creatinine), and time to treatment. Sex, diastolic blood pressure, and hyperlipidemia were also included. To adjust for center-level differences, the unique hospital identifier was also included in the model as a random effect. To exclude the impact of invasive procedure (cardiac catheterization, PCI, or coronary artery bypass surgery), we reran the bleeding model excluding those who had these procedure(s).
Similarly, in-hospital mortality among different categories was compared after adjustment for baseline confounders with multivariate logistic regression analysis. The interaction of race and bleeding was also examined in this model. For all analyses, a 2-tailed value of PϽ0.05 was considered statistically significant. All analyses were performed with SAS statistical software (SAS Institute, Cary, NC).
Results
Baseline Characteristics and Treatments
The numbers of black and white patients receiving fibrinolysis and PPCI for STEMI are shown in Table 1 . Among fibrinolysis patients, blacks treated were younger men with greater body mass index than whites. Comorbid conditions such as history of diabetes mellitus, congestive heart failure, hypertension, previous MI, smoking, stroke, or renal failure were higher among blacks compared with whites. Presentation with anteroseptal STEMI, higher heart rate, and higher diastolic blood pressure was also more common among blacks. In contrast, history of chronic obstructive pulmonary disease, hypercholesterolemia, prior coronary artery bypass surgery, and peak creatine kinase values Ն2 times the upper limit of normal were less frequent in blacks. There was a statistically significant but clinically marginal longer door-toneedle time and higher use within first 24 hours of ␤-blockers but lower use of glycoprotein IIb/IIIa antagonists in blacks. Similarly, a statistically significant but clinically marginally lower use of aspirin was observed among blacks at discharge. Use of invasive procedures and values of left ventricular ejection fraction were lower in general in blacks receiving fibrinolysis.
In patients undergoing PPCI, for the most part, baseline characteristics, presenting features, time to treatment, and use of early and discharge medications were similarly lower or higher to that seen for fibrinolysis in blacks compared with whites ( Table 2 ).
In-Hospital Clinical Events
Among patients receiving fibrinolysis, most clinical adverse events were similar or lower among blacks compared with whites ( Table 3 ). Strokes and hemorrhagic strokes were higher in blacks. In contrast, in patients undergoing PPCI, for the most part, adverse clinical events were similar in blacks compared with whites. Occurrence of atrial fibrillation was lower and recurrent ischemic events higher in Blacks treated with PPCI.
Bleeding and Mortality
Overall, bleeding was higher among blacks treated with any reperfusion therapy (10.6% versus 9.1%; Pϭ0.0026). In patients receiving fibrinolysis, bleeding rates were marginally (not statistically) higher in blacks compared with whites. Bleeding was statistically significantly higher in blacks compared with whites treated with PPCI. The majority of patients with bleeding in both racial groups treated with either fibrinolysis or PPCI received pack red blood cell transfusions. The rate of transfusion was higher among blacks treated with fibrinolysis (albeit statistically nonsignificant) and PPCI (statistically significant) compared with whites treated with the respective reperfusion strategy. Very few of the fibrinolytictreated patients received glycoprotein IIb/IIIa antagonists. In PPCI-treated patients, bleeding was higher in blacks compared with whites regardless of underlying glycoprotein IIb/IIIa antagonist use.
Adjusted odds for bleeding are shown in Table 4 . Bleeding was higher among blacks compared with whites treated with any form of reperfusion (adjusted odds ratio, 1.35; 95% confidence interval, 1.13-1.60). The race-by-treatment interaction term in the multivariable logistic regression model for bleeding in the overall population was statistically significant (PϽ0.001). Among patients treated with fibrinolysis, the adjusted odds for bleeding was significantly higher in blacks (1.21 times) compared with whites (the Figure) . Bleeding remained higher among blacks treated with fibrinolysis who did not undergo either cardiac catheterization or coronary artery bypass surgery. Among PPCItreated patients, the adjusted odds for bleeding was significantly higher among blacks (1.33 times) compared with whites. The adjusted odds for in-hospital mortality are shown in Table 5 . Overall, in-hospital mortality was similar between blacks and whites treated with fibrinolysis (odds ratio, 0.99; 95% confidence interval, 0.70 -1.40) or with PPCI (odds ratio, 1.05; 95% confidence interval, 0.76 -1.46). In patients receiving fibrinolysis or PPCI, bleeding in general was associated with higher mortality than no bleeding. In the fibrinolytic-and PPCI-treated patients, mortality did not differ significantly in the 2 racial groups who did or did not have any bleeding.
Discussion
Our Study Findings
We found that despite younger age and higher body mass index (the 2 most important predictors of bleeding), blacks treated with fibrinolysis had a higher risk of bleeding requiring interventions. The increased bleeding risk in blacks receiving fibrinolysis was observed among both patients who did and those who did not undergo any invasive procedures.
In addition, our study demonstrated for the first time that racial differences in bleeding extended also to those undergoing PPCI. Even among PPCI-treated patients, bleeding was significantly higher in blacks (1.33 times), which was independent of underlying glycoprotein IIb/IIIa use. PPCI indicates primary percutaneous coronary intervention; CABG, coronary artery bypass graft. Overall modelϭrace-by-treatment interaction term, PϽ0.001, and race-by-sex, Pϭ0.2261. Goodness-of-fit P values for bleeding models in the overall population, PPCI-treated patients, and fibrinolytic-treated patients were 0.97, 0.85, and 0.75, respectively.
Figure.
In-hospital mortality stratified by race, bleeding, and reperfusion strategy. PCI indicates percutaneous coronary intervention. Bleeding after either form of reperfusion was associated with a higher risk of in-hospital mortality compared with no bleeding. In patients without any bleeding, mortality did not differ between blacks and whites treated with either fibrinolysis or PPCI. Mortality was also similarly high in the 2 ethnic groups with bleeding after either fibrinolysis or PPCI.
Comparisons With Previous Studies
Previous studies in small case series or those derived from selected cohorts enrolled in clinical trials have suggested that bleeding rates are higher among blacks compared with whites treated with fibrinolysis. 6 -9 The largest of these studies 9 not only demonstrated higher bleeding risk among blacks treated with fibrinolysis but also showed that the higher rate of bleeding was associated with some of the increased risk of deaths seen in blacks treated with this strategy. Enhanced sensitivity to fibrinolysis 6,7 resulting from the genotypic and/or phenotypic differences between the 2 racial groups was speculated as the mechanism underlying this increased risk of bleeding in blacks.
Our results confirmed these observations in a larger community-based cohort of STEMI patients, suggesting higher bleeding rates among black compared with whites treated with fibrinolysis. Our data suggest that higher bleeding in blacks was not observed only after fibrinolysis; a relatively much higher bleeding risk was also seen among blacks compared with whites treated with PPCI. This finding raises the possibility that perhaps other patient-and/or racespecific and/or genetic differences beyond that leading to enhanced fibrinolysis may play an important role in the increased bleeding risk seen in blacks.
Differences in baseline clinical features by race may have predisposed to higher bleeding in blacks, but these differential risks persisted even after accounting for measured baseline confounders. The use of potent antithrombotic agents such as heparin and thienopyridines and the proportion of patients undergoing cardiac catheterization were similar for the most part in the 2 ethnic groups, whereas the use of glycoprotein IIb/IIIa inhibitors and other invasive procedures (PCI, coronary artery bypass surgery, intra-aortic balloon pump) was lower among blacks compared with whites treated with fibrinolysis to explain the higher bleeding in blacks. Additionally, increased bleeding risk in blacks persisted even among patients managed without invasive cardiac procedures, suggesting mechanisms other than that explained by the differential use of these procedures. Differential response to antithrombotic and/or antiplatelet medications (perhaps related to genetic heterogeneity) or the use of these agents that were not adjusted for weight or for creatinine clearance may also account for some of the variations observed.
Finally, consistent with the now emerging novel theme in cardiovascular diseases that "bleeding is not benign," 9, 19 our data also suggest higher mortality in patients with bleeding compared with those without bleeding among fibrinolytic-or PPCI-treated patients of both ethnic groups.
Clinical Implications
The findings of differences by race in the risk of bleeding with either reperfusion strategy highlight the importance of more research in understanding factors underlying these differential risks. Our findings that ethnicity had no influence on in-hospital mortality in the absence of bleeding after either chemical or mechanical reperfusion and that bleeding was consistently associated with increased in-hospital mortality suggest that efforts should be directed at understanding and implementing strategies for reducing bleeding in those receiving either form of reperfusion.
Our findings of similar overall in-hospital mortality among blacks and whites treated with fibrinolysis or PPCI are consistent with results from previous studies that demonstrated that black race was associated independently with 30-day to 1-year mortality 20 but not with death within the first 30 days (short-term mortality) after fibrinolysis for STEMI. 21 The increased risk of bleeding, the higher risk of death beyond 30 days, 20 and the association of bleeding with higher long-term mortality 9 in blacks compared with whites receiving reperfusion suggest that reducing bleeding may have significant potential for improving outcomes beyond the acute phase of those receiving reperfusion in general regardless of underlying race and for narrowing the gap in racerelated disparities in longer-term outcomes.
Finally, variations in outcomes by race in STEMI patients have been described 9 and have been attributed to differences (and complex interactions) in genetic, environmental, and socioeconomic factors, as well as comorbid conditions and lifestyle. Additionally, variability in patient management, use of invasive procedures, and compliance with goals of secondary prevention also have significant influence on the ethnic variations in outcomes. Similarly, the efficacy and/or safety of drugs have been shown to differ among various ethnic groups 22 and may contribute to some of the race-related differences in outcomes. Our data suggest that inferring that the effectiveness and safety of potent drugs (or for that matter any strategy such as PPCI) are similar in other ethnic groups as demonstrated for whites (based on results of large clinical trials comprising mostly whites) may not always be appropriate. Better understanding of any new treatments or strategies is needed by way of clinical trials that include patients with varied ethnic background in sufficiently large numbers, through comparative effectiveness studies using welldesigned large registries, or both.
Limitations
As with most observational studies, some data were missing or incomplete. We are unable to account for the influence of these unmeasured confounders and/or their interactions with measured variables on our study findings. Particularly, we are unable to account for baseline hemoglobin; baseline medications, including oral anticoagulants; and some of the variations associated with specific sites beyond that already adjusted for, including processes or care for quality and safety (timely reperfusion, correct medication doses, etc). The majority of patients with bleeding received blood transfusion. Thus, we are unable to evaluate the association of race and bleeding with in-hospital mortality that is independent of transfusion, a factor shown to be associated with an increased risk of adverse outcomes. 23 NRMI was not designed to address bleeding risks; thus, some pertinent information (such as appropriate dosing of drugs based on the patient's weight and renal function) was not collected and may have accounted for some of the variations seen in bleeding and outcomes. Given these limitations, caution needs to be exercised when the increased bleeding risk in blacks compared with whites is attributed predominantly to phenotypic or genotypic differences. Although this remains a possibility, unmeasured confounders may have accounted for some or all of the variations seen in bleeding and outcomes between the 2 races. Our findings are most applicable to patients with STEMI receiving reperfusion and should not be extrapolated to patients with non-ST-elevation acute coronary syndromes, a population in which no increased risk of bleeding was seen among blacks enrolled in the Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 24 Finally, our data predate the increasing use of radial approach or newer antithrombotic and antiplatelet agents such as bivalirudin, prasugrel, and ticagrelor, and inferences regarding radial approach or these newer agents on ethnic difference in bleeding cannot be made from our data.
Conclusions
In patients with acute STEMI receiving reperfusion, rates of bleeding were significantly higher among blacks not only with fibrinolysis but also with PPCI compared with whites. Bleeding was associated with a similar high mortality in patients of both racial groups treated with either reperfusion strategies. Future research should focus on understanding factors associated with differential bleeding risks by race, evaluating strategies aimed at reducing the risk of bleeding after reperfusion for STEMI. Efforts at reducing bleeding and minimizing the racial variation in bleeding may have a significant potential for improving outcomes for all STEMI patients receiving reperfusion and may represent an opportunity for reducing some of the racial disparities in outcomes.
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